Adjuvant chemotherapy for medulloblastoma and ependymoma using iv vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group Study.
In a prospective, randomized, cooperative group trial, the value of iv vincristine and intrathecal methotrexate and hydrocortisone as adjuvant therapy to radiotherapy in children with medulloblastoma and ependymoma was evaluated. The data showed no improvement in the survival of such children when adjuvant therapy was given.
D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004806:Ependymoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage*; D008527:Medulloblastoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D008727:Methotrexate / Q000008:administration & dosage*; D011336:Probability; D011379:Prognosis; D011879:Radiotherapy Dosage; D011897:Random Allocation; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage*
D014750:Vincristine; D006854:Hydrocortisone; D008727:Methotrexate